Inactive Instrument

RenovaCare, Inc. Stock Other OTC

Equities

RCAR

US75988J1060

Biotechnology & Medical Research

Sales 2020 - Sales 2021 - Capitalization 24.41M
Net income 2020 -9M Net income 2021 -4M EV / Sales 2020 -
Net cash position 2020 7.33M Net cash position 2021 2.82M EV / Sales 2021 -
P/E ratio 2020
-25.6 x
P/E ratio 2021
-5.46 x
Employees -
Yield 2020 *
-
Yield 2021
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 63 21-03-15
Chief Tech/Sci/R&D Officer - 20-06-09
Members of the board TitleAgeSince
Chief Executive Officer 63 18-03-20
More insiders
RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. The Company’s CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from the Company’s novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.
More about the company